CD40 and cancer: Various strategies, such as cell‐based cancer vaccines (GVAX), CD40 agonistic antibodies, and colony‐stimulating factor 1 receptor blockade, have been developed to transform the immunosuppressive pancreatic TME into conditions that can empower an anticancer immune response 28, 42, 43.